Search results for " Interleukin-2"

showing 10 items of 63 documents

Costimulatory signalling potential of murine MHC class II‐positive T‐clone cells

1996

Activated human and rat T cells as well as mouse T-cell clones have been reported to synthesize and express major histocompatibility complex (MHC) class II molecules. However, the capacity of class II+ antigen (Ag) presenting T cells to induce proliferation of Ag-specific cloned T cells has been controversial. We analysed whether the failure of some T-cell clones to proliferate in response to Ag presented by class II+ T cells is because of a lack of costimulatory cytokine production by the antigen-presenting cells (APC). As a model system the mouse class II+ cloned BI/O4.1 T cells were used as APC in order to activate the T cell clone KIII5. This T-helper 1 (Th1) type, GAT (synthetic copoly…

ImmunologyAntigen presentationCD1Antigen-Presenting CellsPolymerase Chain ReactionCell LineMiceInterleukin 21T-Lymphocyte SubsetsAnimalsImmunology and AllergyCytotoxic T cellIL-2 receptorAntigen-presenting cellMice Inbred C3HMHC class IICD40biologyHistocompatibility Antigens Class IIReceptors Interleukin-2Th1 CellsInterleukin-12Molecular biologyMice Inbred C57BLbiology.proteinInterleukin-2Cell DivisionSpleenSignal TransductionResearch ArticleImmunology
researchProduct

β1D Integrin Inhibits Cell Cycle Progression in Normal Myoblasts and Fibroblasts

1998

Integrins are alphabeta heterodimeric transmembrane receptors involved in the regulation of cell growth and differentiation. The beta1 integrin subunit is widely expressed in vivo and is represented by four alternatively spliced cytoplasmic domain isoforms. beta1D is a muscle-specific variant of beta1 integrin and a predominant beta1 isoform in striated muscles. In the present study we showed that expression of the exogenous beta1D integrin in C2C12 myoblasts and NIH 3T3 or REF 52 fibroblasts inhibited cell proliferation. Unlike the case of the common beta1A isoform, adhesion of beta1D-transfected C2C12 myoblasts specifically via the expressed integrin did not activate mitogen-activated pro…

IntegrinsRecombinant Fusion ProteinsMolecular Sequence DataIntegrinSignal transductionTransfectionCell adhesion; Integrins; Signal transduction; Alternative splicing isoforms; Cell proliferation; MyodifferentiationBiochemistryCD49cCell LineCollagen receptorMiceAlternative splicing isoformsCell surface receptorAnimalsAmino Acid SequenceMuscle SkeletalMolecular BiologyCell proliferationMyodifferentiationbiologyCell growthIntegrin beta1Cell CycleCell adhesionCell DifferentiationReceptors Interleukin-2Cell BiologyImmunohistochemistryMolecular biologyCell biologyEnzyme ActivationProto-Oncogene Proteins c-rafAlternative SplicingGenes rasIntegrin alpha MCalcium-Calmodulin-Dependent Protein Kinasesbiology.proteinIntegrin beta 6C2C12Journal of Biological Chemistry
researchProduct

Human CD25+ regulatory T cells: two subsets defined by the integrins alpha 4 beta 7 or alpha 4 beta 1 confer distinct suppressive properties upon CD4…

2004

Down-regulation of autoreactive T cell responses in vivo includes cell-contact-dependent as well as contact-independent mechanisms. Infectious tolerance is a contact-dependent mechanism used by naturally occurring CD25(+) T regulatory cells (Tregs) to confer suppressive activity upon conventional CD4(+) T cells thereby generating secondary T helper suppressor cells(Th(sup)), which inhibit T cell activation via soluble mediators. Here, we describe two distinct subsets of human Tregs, characterized by expression of either the alpha(4)beta(7) integrin or the alpha(4)beta(1) integrin. Upon activation, both subsets show an enhanced expression of FoxP3, recently described as a key transcription f…

IntegrinsbiologyT cellImmunologyIntegrinFOXP3Receptors Interleukin-2T lymphocyteT-Lymphocytes Helper-InducerCell biologyInterleukin-10Interleukin 21medicine.anatomical_structureT-Lymphocyte SubsetsTransforming Growth Factor betaImmunologymedicinebiology.proteinImmunology and AllergyCytotoxic T cellHumansIL-2 receptorBeta (finance)European journal of immunology
researchProduct

A phase-II study of low-dose cyclophosphamide and recombinant human interleukin-2 in metastatic renal cell carcinoma and malignant melanoma.

1989

Recent preclinical and clinical studies that have demonstrated antitumor activity of high-dose recombinant interleukin-2 (rIL-2), and animal models that demonstrated a synergistic effect of low-dose cyclophosphamide, led us to study rIL-2 (Cetus Corp., Emeryville, Calif) in a phase II clinical trial in combination with low-dose cyclophosphamide in 32 patients, 18 with malignant melanoma and 14 with renal cell carcinoma. rIL-2 was given once daily at 3 x 10(6) U/m2, as a 30-min infusion for 14 days in cycle I and for 2 x 5 days in cycles II and III respectively; if tolerated, the dose was increased to a maximum of 6 x 10(6) U m-2 day-1; the cycles, separated by 1 week treatment-free interval…

Interleukin 2AdultMaleCancer Researchmedicine.medical_specialtyPathologyCyclophosphamidemedicine.medical_treatmentImmunologyPhases of clinical researchGastroenterologyDrug Administration ScheduleRenal cell carcinomaInternal medicineAntineoplastic Combined Chemotherapy ProtocolsImmunology and AllergyMedicineHumansNeoplasm MetastasisCyclophosphamideMelanomaAgedChemotherapyKidneybusiness.industryMelanomaCarcinomaRemission InductionReceptors Interleukin-2Middle Agedmedicine.diseaseKidney NeoplasmsRecombinant ProteinsBlood Cell Countmedicine.anatomical_structurePhenotypeOncologyDrug EvaluationInterleukin-2FemaleBolus (digestion)businessmedicine.drugCancer immunology, immunotherapy : CII
researchProduct

Cloned T helper cells reverting to a resting state develop increasing sensitivity in their antigen-mediated interaction with accessory cells.

1988

A cloned murine T cell line, KIII5, specific for the polypeptide poly-L(Tyr,Glu)-poly-D,L-Ala--poly-L-Lys [(T,G)-A--L] was compared at different stages after antigenic stimulation with respect to the conditions required for the reinduction of growth by varying concentrations of antigen presented on different types of accessory cells (AC). We show that the dose of antigen necessary for inducing half maximal proliferation in the presence of splenic AC shifts to considerably lower concentrations when the T cell blasts revert to a resting state (100 micrograms/ml on day 7 to 10 micrograms/ml on day 21-35). During the same time period the expression of interleukin 2 (IL2) receptor and the reacti…

Interleukin 2Antigens Differentiation T-Lymphocytemedicine.medical_specialtyT cellImmunologyAntigen presentationDose-Response Relationship ImmunologicReceptors Antigen T-CellAntigen-Presenting CellsBiologyIn Vitro TechniquesLymphocyte ActivationCell LineMiceImmune systemAntigenInternal medicinemedicineImmunology and AllergyAnimalsAntigen-presenting cellDose-Response Relationship DrugReceptors Interleukin-2T lymphocyteT-Lymphocytes Helper-InducerRecombinant ProteinsClone CellsEndocrinologymedicine.anatomical_structureInterleukin-2Clone (B-cell biology)Immunologic Memorymedicine.drugEuropean journal of immunology
researchProduct

Human interleukin 2: molecular biology, physiology and clinical possibilities.

1986

Interleukin 2Antigens Differentiation T-Lymphocytemedicine.medical_treatmentT-LymphocytesImmunologyPhysiologyGraft vs Host DiseaseCyclosporinsBiologyInterleukine 2MiceNeoplasmsmedicineImmune ToleranceImmunology and AllergyAnimalsHumansReceptors ImmunologicBone Marrow TransplantationMacrophagesLymphokineImmunization PassiveAntibodies MonoclonalImmunosuppressionReceptors Interleukin-2HematologyImmunotherapyRecombinant ProteinsKiller Cells NaturalImmunologyAntigens SurfaceInterleukin-2medicine.drugImmunobiology
researchProduct

The addition of interleukin-2 to cyclophosphamide therapy can facilitate tumor growth of B16 melanoma.

1995

The role of interleukin-2 (IL-2) on tumor growth of B16F10 melanoma cells was assessed in two sets of mice with different immune status: normal (immunocompetent) mice and immunodeficient mice. The two sets of animals were treated with cyclophosphamide (CY) or IL-2 alone or with a combined therapy of CY+IL-2. On days 6 and 10 after tumor cell injection, we evaluated the incidence of hepatic B16 melanoma metastases and the percentage of hepatic volume occupied by metastatic tissue. We observed that the CY alone (300 mg/kg, days 3 and 8 post-tumoral inoculation) significantly reduced tumor growth in all treated mice; however, CY proved more effective in normal recipients than in immunodeficien…

Interleukin 2Cancer ResearchPathologymedicine.medical_specialtyCyclophosphamideRatónmedicine.medical_treatmentImmunologyMelanoma ExperimentalInjectionsAndrologychemistry.chemical_compoundImmunocompromised HostMiceIn vivomedicineImmunology and AllergyAnimalsImmunologic FactorsDrug InteractionsCyclophosphamideChemotherapybusiness.industryLiver NeoplasmsReceptors Interleukin-2Combined Modality TherapyNitrogen mustardNeoplasm ProteinsMice Inbred C57BLCytokineOncologychemistryToxicityInterleukin-2FemalebusinessImmunocompetenceNeoplasm TransplantationSpleenWhole-Body Irradiationmedicine.drugCancer immunology, immunotherapy : CII
researchProduct

The significance of serum soluble IL-2 receptor as a marker for active visceral leishmaniasis in Sicilian patients

1992

SUMMARY Sera from nine Sicilian patients with confirmed visceral leishmaniasis (Leishmania donovani infantum; VL), at the moment of the diagnosis, during the course of the disease and after clinical recovery, were analysed for the concentration of soluble IL-2 receptor (sIL-2R). The results show that sIL-2R is a marker of disease activity, since it is in high concentration at the beginning of infection and returns to the normal range following successful chemotherapy. At the same time of serum analysis for sIL-2R, peripheral blood mononuclear cells (PBMC) of VL patients were stimulated with phytohaemagglutinin (PHA) or antigen and supernatant tested for IL-2 and interferon-gamma (IFN-γ) pro…

Interleukin 2ImmunologyLeishmania donovaniBiologyPeripheral blood mononuclear cellInterferon-gammaAntigenmedicineAnimalsHumansImmunology and AllergyIL-2 receptorSicilyPhytohaemagglutininReceptors Interleukin-2Leishmaniasismedicine.diseasebiology.organism_classificationVisceral leishmaniasisSolubilityImmunologyLeukocytes Mononuclearbiology.proteinInterleukin-2Leishmaniasis VisceralLeishmania donovaniResearch Articlemedicine.drugClinical and Experimental Immunology
researchProduct

Langerhans Cells Prevent Autoimmunity via Expansion of Keratinocyte Antigen-Specific Regulatory T Cells

2017

Langerhans cells (LCs) are antigen-presenting cells in the epidermis whose roles in antigen-specific immune regulation remain incompletely understood. Desmoglein 3 (Dsg3) is a keratinocyte cell-cell adhesion molecule critical for epidermal integrity and an autoantigen in the autoimmune blistering disease pemphigus. Although antibody-mediated disease mechanisms in pemphigus are extensively characterized, the T cell aspect of this autoimmune disease still remains poorly understood. Herein, we utilized a mouse model of CD4+ T cell-mediated autoimmunity against Dsg3 to show that acquisition of Dsg3 and subsequent presentation to T cells by LCs depended on the C-type lectin langerin. The lack of…

Keratinocytes0301 basic medicineLangerinRegulatory T cellT celllcsh:MedicineAutoimmunitymedicine.disease_causeT-Lymphocytes RegulatoryGeneral Biochemistry Genetics and Molecular BiologyAutoimmunity03 medical and health sciencesAutoimmune diseasemedicineAnimalsLectins C-TypeAntigenseducationCell ProliferationAutoimmune diseaselcsh:R5-920Antigen Presentationeducation.field_of_studyDesmoglein 3integumentary systembiologylcsh:RHistocompatibility Antigens Class IIPeripheral toleranceReceptors Interleukin-2Regulatory T cellsGeneral Medicinemedicine.diseaseCell biologyMice Inbred C57BLPemphigusMannose-Binding Lectins030104 developmental biologymedicine.anatomical_structureLangerhans CellsAntigens SurfaceDesmoglein 3biology.proteinlcsh:Medicine (General)PemphigusResearch PaperSignal TransductionEBioMedicine
researchProduct

Long-term pertussis-specific immunity after primary vaccination with a combined diphtheria, tetanus, tricomponent acellular pertussis, and hepatitis …

2001

ABSTRACT The aim of this study was to compare pertussis-specific humoral and cellular immunity in children 5 years after a primary vaccination with a combined diphtheria, tetanus, tricomponent acellular pertussis, and hepatitis B vaccine (DTaP-HBV; InfanrixHepB; SmithKline Beecham) with immunity after natural infection. The subjects were 38 children aged 5 to 6 years who received DTaP-HBV at 3, 5, and 11 months of life and 21 subjects of similar ages and sex who acquired pertussis in the first year of life. Immunoglobulin G (IgG) antibody titers against Bordetella pertussis antigens, peripheral blood mononuclear cell-specific proliferation, and the secretion of cytokines were evaluated. Aft…

MaleBordetella pertussisCellular immunityTime FactorsHepatitis B vaccineWhooping CoughImmunologyMicrobiologyBordetella pertussisAntibodiesInterferon-gammaImmunitymedicineHumansHepatitis B VaccinesSingle-Blind MethodVaccines CombinedLymphocytesChildPreschoolDiphtheria-Tetanus-Pertussis VaccineWhooping coughHaemophilus VaccinesVaccinesbiologyVaccines; Combined; Interferon-gamma; Humans; Whooping Cough; Hepatitis B Vaccines; Child; Lymphocytes; Diphtheria-Tetanus-Pertussis Vaccine; Vaccination; Preschool; Bordetella pertussis; Single-Blind Method; Interleukin-2; Antibodies; Bacterial; Haemophilus Vaccines; Interleukin-4; Interleukin-5; Time Factors; Male; Female; Cell DivisionCombinedTetanusbusiness.industryDiphtheriaCELL-MEDIATED-IMMUNITYVaccinationBacterialbiology.organism_classificationmedicine.diseaseAntibodies BacterialVirologyVaccinationInfectious DiseasesChild PreschoolMicrobial Immunity and VaccinesImmunologyInterleukin-2FemaleParasitologyInterleukin-4Interleukin-5businessCell Division
researchProduct